TC
DAWN

Torno Capital’s Day One Biopharmaceuticals DAWN Stock Holding History

Torno Capital’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,000
Closed -$413K – 234
2024
Q2 		$413K Buy
+30,000
New +$439K 0.02% 124

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Torno Capital's DAWN Position: Q3 2024 in Review

Torno Capital sold out of Day One Biopharmaceuticals (DAWN) in Q3 2024, closing a stake of 13,037 shares — an estimated $180K sold.

Torno Capital first reported a position in DAWN in Q2 2024 and held it in 1 quarter. The position peaked at $180K in Q2 2024. 166 funds tracked by Wall St. Rank hold DAWN as of Q3 2024.

  • Torno Capital reported no remaining Day One Biopharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Torno Capital sold 13,037 Day One Biopharmaceuticals shares in Q3 2024, an estimated $180K.
  • Torno Capital first reported a position in Day One Biopharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Torno Capital's Day One Biopharmaceuticals position peaked at $180K in Q2 2024.
  • 166 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2024.

Based on Torno Capital's 13F filing for Q3 2024, filed 13 Nov 2024.